XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 32.48

+0.7%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert K. who wrote (13726)	5/31/2000 11:43:00 PM
From: Bluegreen	Read Replies (2) of 17367

WOW>>>>>>>>>>Therapeutic and epidemiological significance of decreased susceptibility to penicillin in Neisseria meningitidis in the UK PHLS Meningococcal Reference Unit, Manchester N. meningitidis is now the major cause of bacterial meningitis. Penicillin remains the antibiotic of choice for the treatment of meningococcal disease. Meningococcal isolates with decreased susceptibility to penicillin are becoming more common in the United Kingdom and elsewhere arousing concerns about the continued therapeutic efficacy of penicillin. There is an urgent need to determine the therapeutic and epidemiological significance of altered susceptibility to penicillin for meningococcal infection in the UK. Clinical and epidemiological information for cases of infection due to organisms with reduced susceptibility to penicillin will be studied to determine the descriptive epidemiology. The molecular epidemiology will be studied by analysis of the nucleotide sequence variation for the meningococcal penicillin binding protein-2 gene (penA) for representative case isolates which are sensitive and show reduced susceptibility to penicillin. Multilocus sequence typing (MLST) will be used to identify strain associations with altered penicillin susceptibility. The penA and MLST analysis will be adapted for the direct analysis of specimens from non-culture confirmed cases. The clinical and molecular epidemiological data will be analysed to examine the therapeutic importance of altered susceptibility to penicillin and to generate hypotheses for more formal testing.<<<<<<<<< And look at this, notice figures of mortality in shock AND notice value of time. You need to give Neuprex IMMEDIATELY just like antibiotics. What morons helped Xoma design a trial which allowed so much time before Neuprex was given to the kids???? And then they have the gall to say they need a better p value??? UNDER SUBPART E????? What a pathetic situation. Just plain old pathetic. Probably just as pathetic as Xoma waiting to publish Meningo. data. Everyone should be telling their Politicians about all of this and anyone else who will listen ....NOW! Show some BACKBONE Xoma, RELEASE THE DATA NOW!! Who cares who publishes it....IT STILL WON'T CHANGE THE DATA!!! ANYONE WITH HALF A BRAIN CAN READ AND EVALUATE THE DATA!!! PUBLISHING IN HIGH BROW PUBLICATION WILL NOT CHANGE THE DATA!!!! In my opinion public pressure will work the quickest. Isn't PUBLIC pressure better and quicker than any POSSIBLE medical pressure from publishing in a high brow publication???? Shouldn't everyone who owns XOMA STOCK DEMAND THAT XOMA RELEASE THE DATA NOW??? STOCKHOLDERS OWN THE COMPANY........THE BOARD SERVES THE STOCKHOLDERS AND CAN BE REPLACED!!! And remember the board doesn't own that much stock!!!! RELEASE THE DATA NOW!!!>>>>>>>>>>Health care delivery and outcome of meningococcal disease in children Imperial College School of Medicine at St Mary's and Royal College of Paediatrics and Child Health Meningococcal infection remains an important cause of childhood morbidity and mortality. Most deaths in meningococcal infection are due to meningococcal septicaemia rather than meningitis. Despite the availability of potent antibiotics to which the meningococcus bacterium is highly sensitive, the overall mortality rate remains at 10%, increasing to 40% in patients who present in shock. There are two likely major factors responsible for the continued high mortality from meningococcal shock: 1. Ineffective treatment of the pathophysiology of meningococcal shock. 2. Health care delivery: children with meningococcal septicaemia may develop profound shock and die within 24-48 hours of the first symptom. Delay or inappropriate treatment at any stage in the interaction of the child and health care system may adversely affect the prognosis. The present study aims to ú document all deaths in children under 17 years caused by meningococcal disease over a 2-year period in England and Wales. ú conduct a case controlled study based on these subjects to compare the standard of health care delivery in fatal and non-fatal cases. Factors to be compared will include: time between onset of illness and institution of appropriate management by GP's, casualty officers, and the paediatric team; whether the patients were managed on a general paediatric ward or intensive care unit; delays incurred (if any) in gaining access to an intensive care unit; and the adequacy and extent of measures used to treat circulatory collapse, impaired perfusion, raised intracranial pressure and organ failure.<<<<<<<<<<

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next